ADC Therapeutics raises $200m to advance antibody-based cancer treatments
Our client, ADC Therapeutics (ADCT), has raised $200m in private financing to fund registrational trials of its two lead cancer programs. Investors include: Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.
The Swiss based company develops antibody drug conjugates that target major cancers by incorporating highly potent pyrrolobenzodiazepine-based warheads. Its clinical and preclinical programs target major forms of hematological malignancies and solid tumours.
Earlier this month, ADCT triggered a second target-specific license with Netherlands-based biotechnology company, Synaffix, to develop an antibody-drug conjugate using Synaffix’s proprietary site-specific antibody-drug conjugation technology.